GlycA measures the aggregate signal from several acute-phase glycoproteins using NMR spectroscopy. Unlike CRP, which reflects a single acute-phase protein, GlycA integrates inflammatory signaling from multiple sources and tends to be more stable over time.
GlycA is emerging as a superior chronic inflammation marker in longevity circles because it captures persistent low-grade inflammation more reliably than hs-CRP, which fluctuates with transient infections and minor injuries. Elevated GlycA correlates with cardiovascular events, type 2 diabetes, and all-cause mortality in large cohort studies. It's not yet in standard clinical panels but is increasingly available through advanced metabolic panels.
Optimal GlycA: 0-350 µmol/L.
Typically re-tested every 12 weeks.
GlycA is a composite blood measurement of the sugar groups attached to several inflammation related proteins circulating in plasma, reported as a single number in µmol/L.
The measurement comes from nuclear magnetic resonance (NMR) spectroscopy run on a plasma or serum sample, usually as part of a broader metabolomic or advanced lipoprotein profile. The signal arises from the N-acetyl methyl groups of N-acetylglucosamine residues sitting on the glycan chains of acute phase glycoproteins. The main contributors are alpha-1-acid glycoprotein, haptoglobin, alpha-1-antitrypsin, alpha-1-antichymotrypsin and transferrin.
The mechanism is worth understanding, because it explains what the number can and cannot tell you. When inflammatory signalling rises anywhere in the body, the liver increases production of these acute phase glycoproteins and also changes how they are glycosylated. Both shifts, more protein and more branching on the sugar chains, push the composite peak upward. So GlycA is not a measure of one pathway. It is a summed readout of several, weighted toward the liver's response to inflammatory cytokines.
That composite nature gives GlycA a different personality from the single protein markers most people have seen on a lab report. A high sensitivity CRP can swing enormously during an acute infection and then fall back within days. GlycA tends to move less violently and to track a person's background inflammatory state more steadily across months. Laboratories regard it as a marker of chronic inflammatory burden rather than a test for acute illness, which is why it shows up in cardiometabolic and longevity panels rather than in urgent care workups.
It matters because chronic low grade inflammation is one of the shared mechanisms underneath cardiovascular disease, insulin resistance and several inflammatory conditions, and GlycA is one of the more stable ways to put a number on it.
The cardiovascular link is where most of the published work sits. In an analysis using coronary computed tomography angiography, increased glycoprotein acetylation was associated with higher cardiac event rates 1. A separate population based study found that a metabolic risk score built from NMR measured markers added incremental value for predicting heart failure mortality 2. Neither finding means a single GlycA value predicts an individual outcome. They mean the marker carries information about population level risk that standard lipids alone do not fully capture.
GlycA also sits close to metabolic biology, not just immune biology. Research in women found that plasma branched-chain amino acid levels were associated with biomarkers of inflammation and lipid metabolism, including glycoprotein acetylation 3. That overlap is part of why GlycA often moves in the same direction as insulin resistance, central adiposity and atherogenic lipid patterns.
The marker is responsive to changes in inflammatory disease activity too. In people with systemic lupus erythematosus, a study examining type I interferon inhibition reported modulation of cardiometabolic disease markers 4. In people with psoriasis, a randomised placebo controlled trial assessed the effect of two psoriasis therapies on vascular inflammation and novel inflammatory cardiovascular biomarkers 5. Taken together, GlycA appears to behave as a dynamic reflection of systemic inflammatory activity rather than a fixed trait.
What that means practically is simple. One GlycA value is a snapshot of inflammatory tone. A series of values over time, read alongside lipids, glucose and other inflammatory markers, is far more informative, and is the sort of pattern worth reviewing with a clinician.
A typical lab reference range for GlycA is 0 to 400 µmol/L, and FitScript's optimal range is tighter at 0 to 350 µmol/L.
| Marker | Typical lab reference range | FitScript optimal range | Units |
|---|---|---|---|
| GlycA | 0 to 400 | 0 to 350 | µmol/L |
Optimal ranges are FitScript's optimization targets, not diagnostic cut-offs, and a result outside an optimal range is a prompt for context rather than a verdict. Reference ranges vary by lab, age and sex, and the NMR platform and calibration used by the testing laboratory matter as well, so always read your value against the range printed on your own report.
Two further points help with interpretation. First, there is no established lower limit of concern for GlycA, which is why both ranges start at zero. Second, population averages differ by sex and tend to drift upward with age and with increasing body fat, so a value that looks ordinary for a population may still be higher than ideal for an individual. The useful question is not only whether the number falls inside a range, but where it sits within that range and which direction it has moved since the last test.
A high GlycA result suggests elevated chronic inflammatory activity somewhere in the body, and it points toward a search for the reason rather than toward any single conclusion.
Symptoms people report. GlycA itself causes no symptoms, and many people with an elevated value feel entirely well. Some describe persistent fatigue, slower recovery from training, morning joint stiffness, low grade aches, poor sleep quality or a run of minor infections. These are non-specific and can accompany many different states, so they support the picture rather than explain it.
Common causes. Recent or ongoing infection, injury or surgery raises acute phase proteins and can lift GlycA temporarily. Chronic inflammatory and autoimmune conditions are a frequent driver, as the lupus and psoriasis research above illustrates 4 5. Excess body fat, insulin resistance and smoking are commonly associated with higher values. Diet plays a part too. A systematic review of dietary patterns and inflammatory markers during pregnancy found associations between eating patterns and circulating inflammatory markers 6, and a metagenomics study in overweight and obese pregnant women described distinct diet, microbiota and metabolism interactions 7. Even single meals can shift vascular and lipid measures, as a randomised controlled trial of postprandial responses to different fat spreads in healthy adults reported 8. Pregnancy and oestrogen containing medications also alter acute phase protein levels, which can change the reading.
Long-term health impact. Studies indicate that higher glycoprotein acetylation is associated with higher cardiac event rates 1 and that inflammation weighted metabolic scores carry information about heart failure mortality at population level 2. An elevated value is best read as a marker of accumulated inflammatory burden, which is a modifiable risk signal, not an illness.
What is worth doing next. Note any recent infection, vaccination, injury or very hard training block, since any of these can inflate a single reading. A repeat test once you have been well for several weeks tells you far more than one number. A persistently elevated result, or one accompanied by symptoms, is worth discussing with a clinician promptly so the underlying cause can be investigated properly.
A low GlycA result is generally the favourable direction and usually indicates low background inflammatory activity rather than a deficiency of anything.
Symptoms people report. There are no symptoms attributable to a low GlycA. Unlike a vitamin or a hormone, GlycA is not a substance the body needs a minimum amount of. It is a by-product signal of inflammatory protein production, so less of it reflects a quieter inflammatory state.
Common causes. A low value is commonly seen alongside lean body composition, good cardiorespiratory fitness, non-smoking status, adequate sleep and the absence of active infection or autoimmune activity. Medications and therapies that dampen inflammatory signalling can also lower the reading, which is part of why the marker is studied as a response measure in inflammatory disease. Laboratory and sample handling factors, and recent anaesthesia or sedation, can influence NMR derived metabolite measures as well, as a randomised trial of several anaesthetic agents on the human metabolome illustrates 9.
Long-term health impact. Lower inflammatory burden is associated with better long-term cardiometabolic outcomes, but a low GlycA is not a clean bill of health. It says little about blood pressure, lipoprotein particle number, glucose control, kidney function or anything structural. Risk can be present with a perfectly quiet inflammatory profile.
What is worth doing next. Keep the value as a baseline, retest periodically to see which way it drifts, and read it alongside the rest of your panel rather than in isolation.
Several things can move a GlycA value, which is why timing and context matter as much as the number itself.
Testing conditions. Acute infection, a recent vaccination, dental inflammation, injury, surgery and intense unaccustomed exercise can all raise acute phase proteins for days to weeks. Recent anaesthesia or sedation can shift the measured metabolome, including NMR derived inflammatory signals 9. Fasting status, time of day, hydration and the specific NMR platform used all introduce some variation, so comparing results across different laboratories is less reliable than tracking the same laboratory over time.
Medications and therapies. Agents that modify inflammatory signalling can change the reading. A secondary analysis of a randomised controlled trial in gestational diabetes examined metformin and insulin in relation to inflammatory markers and IGF-binding protein-1 10. Research in systemic lupus erythematosus reported modulation of cardiometabolic markers with type I interferon inhibition 4, and the psoriasis trial above measured changes in inflammatory cardiovascular biomarkers alongside vascular inflammation 5. None of this is a reason to start, stop or change any medication on your own. A licensed provider evaluates whether any prescription therapy is appropriate for a given person, and no dosing or schedule should be inferred from an inflammatory marker.
Habits and body composition. Body fat, particularly visceral fat, is one of the more consistent correlates of chronic inflammatory markers. Smoking, chronic sleep restriction, alcohol intake and low physical activity are associated with higher inflammatory tone. Diet contributes through several routes. Dietary patterns have been associated with circulating inflammatory markers 6, gut microbial composition interacts with diet and host metabolism 7, meal fat composition influences postprandial lipid and vascular responses 8, and circulating branched-chain amino acids track with inflammatory and lipid biomarkers 3. These levers may matter at population level, though individual response varies and no single change reliably produces a given number.
FitScript does not currently test GlycA in a panel, so this marker is not part of the 150+ biomarkers tested per year that come with membership.
If you already have a GlycA result from another laboratory, you can upload your labs and Atlas, FitScript's AI health advisor, will read it alongside the rest of your markers rather than in isolation. That matters for a composite inflammatory signal, because the useful interpretation almost always comes from the company it keeps. A GlycA sitting above the optimal range next to a normal fasting insulin, clean lipids and no symptoms reads very differently from the same value next to rising fasting glucose and an elevated particle count.
Atlas writes your FitScript from that combined picture, flagging which patterns are worth attention and which measures are worth repeating and when. Where a result raises a question that needs clinical judgement, or where a prescription option might be relevant, a licensed provider reviews the member and decides whether anything is appropriate. An AI interpretation is a reading of your data, not a clinical decision.
GlycA is most informative when read with other inflammatory and metabolic markers, because each one captures a different slice of the same biology.
C-Reactive Protein is the most widely available acute phase marker and moves sharply with acute inflammation, which makes it a useful contrast to the slower moving GlycA signal. Interleukin-6 sits further upstream as one of the cytokines that drives liver production of acute phase proteins in the first place. ESR is an older, non-specific measure of inflammation that is still used routinely in inflammatory and autoimmune assessment. Fibrinogen Activity bridges inflammation and clotting, and is itself an acute phase protein. HOMA-IR estimates insulin resistance, which is one of the metabolic states most consistently associated with higher chronic inflammatory markers. Homocysteine adds a separate vascular risk angle tied to B vitamin status and methylation.
Read together, these markers help answer the question a single GlycA cannot, which is whether an elevated inflammatory signal is acute, chronic, metabolically driven or related to an underlying inflammatory condition.
GlycA is a composite NMR signal that summarises the sugar groups on several acute phase glycoproteins, and it behaves as a relatively stable measure of chronic inflammatory burden. Typical lab reference ranges run to 400 µmol/L, while FitScript's optimal range is 0 to 350 µmol/L. Higher values are associated with cardiometabolic risk, lower values suggest a quieter inflammatory state without guaranteeing anything, and the number is most useful tracked over time alongside other markers. This page is educational and is not medical advice. Discuss your results, and any treatment decision, with a clinician or licensed provider who can see your full history.
It measures a composite nuclear magnetic resonance signal produced by the sugar groups on several acute phase glycoproteins in plasma, chiefly alpha-1-acid glycoprotein, haptoglobin, alpha-1-antitrypsin, alpha-1-antichymotrypsin and transferrin. Because it sums several proteins at once, it reflects chronic inflammatory tone rather than a single pathway.
A typical lab reference range runs from 0 to 400 µmol/L, and FitScript's optimal range is 0 to 350 µmol/L. Optimal ranges are optimization targets, not diagnostic cut-offs. Reference ranges vary by lab, age and sex, so read your value against the range printed on your own report.
Neither replaces the other. CRP responds sharply to acute inflammation and can swing widely within days, while GlycA pools several acute phase proteins and tends to drift more slowly, which makes it useful as a measure of background inflammatory burden. Read together they give more information than either alone.
Higher glycoprotein acetylation is associated with higher cardiac event rates at population level, and inflammation weighted metabolic scores are associated with heart failure mortality. That is risk information, not a diagnosis. A single elevated value means the cause is worth investigating with a clinician alongside your lipids, glucose and blood pressure.
Yes, temporarily. Infection, vaccination, injury, recent surgery and intense unaccustomed exercise all raise acute phase proteins and can lift the reading for days to weeks. If any of those applied when you were tested, repeating the test once you have been well for several weeks gives a more representative value.
Dietary patterns, meal fat composition, gut microbial composition, body fat, smoking, sleep and physical activity are all associated with chronic inflammatory markers. Individual response varies and no single change reliably produces a specific number, so track the trend over repeated tests rather than chasing one result.
There is no established lower limit of concern, which is why both the typical reference range and the optimal range start at zero. A low value generally reflects a quiet inflammatory state. It does not rule out risk from lipids, glucose, blood pressure or anything structural.
FitScript does not currently test GlycA in a panel. If you already have a result from another laboratory, you can upload your labs so Atlas can read it alongside your other markers. Where a result raises a clinical question, a licensed provider reviews the member and decides what is appropriate.